Literature DB >> 21193589

iNOS expression in vascular resident macrophages contributes to circulatory dysfunction of splanchnic vascular smooth muscle contractions in portal hypertensive rats.

Masahiro Kajita1, Takahisa Murata, Kazuhide Horiguchi, Masateru Iizuka, Masatoshi Hori, Hiroshi Ozaki.   

Abstract

Portal hypertension, a major complication of cirrhosis, is caused by both increased portal blood flow due to arterial vasodilation and augmented intrahepatic vascular resistance due to sinusoidal constriction. In this study, we examined the possible involvement of resident macrophages in the tone regulation of splanchnic blood vessels using bile duct ligated (BDL) portal hypertensive rats and an in vitro organ culture method. In BDL cirrhosis, the number of ED2-positive resident macrophages increased by two- to fourfold in the vascular walls of the mesenteric artery and extrahepatic portal vein compared with those in sham-operated rats. Many ED1-positive monocytes were also recruited into this area. The expression of inducible nitric oxide (NO) synthase (iNOS) mRNA was increased in the vascular tissues isolated from BDL rats, and accordingly, nitrate/nitrite production was increased. Immunohistochemistry revealed that iNOS was largely expressed in ED1-positive and ED2-positive cells. We further analyzed the effect of iNOS expression on vascular smooth muscle contraction using an in vitro organ culture system. iNOS mRNA expression and nitrate production significantly increased in vascular tissues (without endothelium) incubated with 1 μg/ml lipopolysaccharide (LPS) for 6 h. Immunohistochemistry indicated that iNOS was largely expressed in ED2-positive resident macrophages. α-Adrenergic-stimulated contractility of the mesenteric artery was greatly suppressed by LPS treatment and was restored by N(G)-nitro-L-arginine methyl ester (NO synthase inhibitor); in contrast, portal vein contractility was largely unaffected by LPS. Sodium nitroprusside (NO donor) and 8-bromo-cGMP showed greater contractile inhibition in the mesenteric artery than in the portal vein with decreasing myosin light chain phosphorylation. In the presence of an α-adrenergic agonist, the mesenteric artery cytosolic Ca(2+) level was greatly reduced by sodium nitroprusside; however, the portal vein Ca(2+) level was largely unaffected. These results suggest that the induction of iNOS in monocytes/macrophages contributes to a hypercirculatory state in the cirrhosis model rat in which the imbalance of the responsiveness of visceral vascular walls to NO (mesenteric artery >> portal vein) may account for the increased portal venous flow in portal hypertension.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21193589     DOI: 10.1152/ajpheart.00563.2009

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  9 in total

1.  Upregulation of inducible nitric oxide synthase contributes to attenuated cutaneous vasodilation in essential hypertensive humans.

Authors:  Caroline J Smith; Lakshmi Santhanam; Rebecca S Bruning; Anna Stanhewicz; Dan E Berkowitz; Lacy A Holowatz
Journal:  Hypertension       Date:  2011-09-19       Impact factor: 10.190

Review 2.  Current concepts on the role of nitric oxide in portal hypertension.

Authors:  Liang Shuo Hu; Jacob George; Jian Hua Wang
Journal:  World J Gastroenterol       Date:  2013-03-21       Impact factor: 5.742

3.  Glycyrrhizinate reduces portal hypertension in isolated perfused rat livers with chronic hepatitis.

Authors:  Xin Zhao; Bo Deng; Xue-Yan Xu; Shi-Jun Yang; Tao Zhang; Yi-Jun Song; Xiao-Ting Liu; Yue-Qi Wang; Da-Yong Cai
Journal:  World J Gastroenterol       Date:  2013-09-28       Impact factor: 5.742

4.  Discovery and validation of novel protein markers in mucosa of portal hypertensive gastropathy.

Authors:  Ying Zhu; Wen Xu; Wei Hu; Fang Wang; Yan Zhou; Jianguo Xu; Wei Gong
Journal:  BMC Gastroenterol       Date:  2021-05-10       Impact factor: 3.067

5.  Glutamine prevents oxidative stress in a model of portal hypertension.

Authors:  Gilmara Pandolfo Zabot; Gustavo Franco Carvalhal; Norma Possa Marroni; Francielli Licks; Renata Minuzzo Hartmann; Vinícius Duval da Silva; Henrique Sarubbi Fillmann
Journal:  World J Gastroenterol       Date:  2017-07-07       Impact factor: 5.742

6.  Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome.

Authors:  Theresa Bucsics; Elisabeth Krones
Journal:  Gastroenterol Rep (Oxf)       Date:  2017-04-24

7.  Salvianolic Acid B reducing portal hypertension depends on macrophages in isolated portal perfused rat livers with chronic hepatitis.

Authors:  Xin Zhao; Hongmei Jia; Shijun Yang; Yuetao Liu; Bo Deng; Xueyan Xu; Tao Zhang; Hang Zhou; Chengzhe Zu; He Yin; Ting Li; Yijun Song; Yueqi Wang; Pengtao Li; Zhongmei Zou; Dayong Cai
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-16       Impact factor: 2.629

8.  Nitro-oxidative stress, VEGF and MMP-9 in patients with cirrhotic and non-cirrhotic portal hypertension.

Authors:  Leon Adrian Muti; Alina Elena Pârvu; Alexandra M Crăciun; Nicolae Miron; Monica Acalovschi
Journal:  Clujul Med       Date:  2015-04-15

Review 9.  Biology of portal hypertension.

Authors:  Matthew McConnell; Yasuko Iwakiri
Journal:  Hepatol Int       Date:  2017-10-26       Impact factor: 6.047

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.